-
PA-Ψ-seq Maps Pseudouridine on Cellular and HIV-1 RNA
2026-08-24
Martinez Campos et al. introduce photo-crosslinking-assisted Ψ sequencing (PA-Ψ-seq), an antibody-based method for mapping pseudouridine residues across cellular and HIV-1 RNAs. Their results assign several cellular mRNA sites to PUS1, PUS7, or TRUB1/PUS4, while showing that pseudouridine on HIV-1 transcripts is unaffected by loss of these enzymes.
-
Dihydroartemisinin Research Workflows
2026-08-24
Build reproducible Dihydroartemisinin assays by controlling solvent handling, exposure design, and orthogonal readouts across parasite and mammalian-cell models. This guide translates antiplasmodial assay logic from a phebestin study into practical workflows for mTOR, inflammation, and psoriasis research without confusing compound-specific evidence.
-
Pravastatin Sodium: Assay Workflows & Applications
2026-08-23
Pravastatin sodium provides a practical, selective way to suppress cholesterol biosynthesis in macrophage, hepatocyte, and metabolic disease models. This guide connects dose design with transporter-aware cytotoxicity testing, helping researchers distinguish target engagement from nonspecific loss of cell function.
-
2',7'-Dichlorofluorescein Diacetate for ROS
2026-08-22
2',7'-Dichlorofluorescein diacetate is a cell-permeable fluorogenic probe for intracellular ROS measurement and general oxidative-stress profiling. Its fluorescent product reports integrated redox activity rather than a single reactive species, so controls and orthogonal validation are essential.
-
Norovirus Co-opts NINJ1 for Selective Protein Secretion
2026-08-22
Song et al. show that murine norovirus repurposes the membrane-rupture protein NINJ1 to release the viral immune-modulatory protein NS1, while still permitting broad damage-associated molecular pattern release. The study combines CRISPR screening, infection models, protein-interaction analysis, mutagenesis, and mouse experiments to define an unconventional secretion mechanism that is relevant to enteric viral pathogenesis.
-
Scalable iMSC-EV Manufacturing for Pulmonary Fibrosis
2026-08-21
Gong et al. developed a bioreactor-based platform that generates induced mesenchymal stem cells from extended pluripotent stem cells and produces extracellular vesicles at a scale relevant to translational research. The resulting iMSC-EVs retained key characteristics and therapeutic activity of primary MSC-EVs in a bleomycin-induced pulmonary fibrosis model, while addressing major manufacturing barriers such as donor variability and limited expansion.
-
GOB-38 in Elizabethkingia anophelis: Substrate Specificity
2026-08-20
The reference study characterizes GOB-38, a B3-Q metallo-β-lactamase from Elizabethkingia anophelis, and shows that its substrate range includes penicillins, multiple cephalosporin generations, and carbapenems. Recombinant expression, biochemical testing, genomic analysis, and co-culture experiments connect enzyme structure with clinically relevant resistance and raise the possibility that co-infecting bacteria may acquire carbapenem resistance.
-
CNQX Workflow for AMPA/Kainate Circuit Studies
2026-08-20
CNQX provides a practical way to separate AMPA/kainate-driven excitation from NMDA-dependent signaling in neuronal and autonomic circuit assays. This workflow connects receptor pharmacology with the cNTS–PVN cardiovascular study, emphasizing local delivery, matched controls, solution handling, and interpretation of negative results.
-
HRP Goat Anti-Mouse IgG (H+L) Antibody
2026-08-19
K1221 provides an HRP-labeled, affinity-purified goat polyclonal secondary antibody for detecting mouse-derived IgG in Western blotting, ELISA, IHC, and ICC. It should be paired with a validated mouse primary antibody and should not be treated as a universal reagent for non-mouse primaries, unvalidated tissue backgrounds, or applications requiring a non-HRP detection chemistry.
-
SARS-CoV-2 NSP15 Inhibitors: Screening Insights
2026-08-19
The 2021 reference study used structure-based virtual screening and molecular dynamics simulations to identify thymopentin and oleuropein as high-priority candidate inhibitors of SARS-CoV-2 NSP15. Its main contribution is a computational route toward targeting viral immune evasion, although biochemical, cellular, pharmacokinetic, and clinical validation remain necessary.
-
E3 Deletion and CAdV-2 Pathogenicity in Dogs
2026-08-18
The reference study identified a novel canine adenovirus type 2 strain carrying a 9-nucleotide E3 deletion that truncated the encoded protein by three amino acids. Experimental canine infections showed that this variant retained virulence comparable to wild-type isolates, emphasizing that E3 sequence variation should not automatically be interpreted as attenuation.
-
Entecavir: From Polymerase Mechanism to Translation
2026-08-18
Entecavir, also known as BMS200475, illustrates how a precisely defined antiviral mechanism can guide resistance modeling, cccDNA interpretation, assay design, and translational strategy. This thought-leadership review connects molecular pharmacology with experimental execution and clinical relevance in chronic hepatitis B research.
-
Human iPSC Sensory Neurons Model HSV-1 Latency
2026-08-17
Oh et al. establish a scalable human induced pluripotent stem cell-derived sensory neuron system that supports HSV-1 latency and stimulus-induced reactivation. The model combines neuronal functional validation with virological, transcriptional, and chromatin-based criteria, providing a stronger human-relevant platform for studying latency mechanisms and evaluating future interventions.
-
From CRISPR Hits to RNA-Ready Translation
2026-08-17
A mechanistic and strategic guide to using T7 RNA polymerase transcription to validate PCMT1-driven ovarian cancer biology, design functional RNA experiments, and evaluate high-yield synthesis platforms for translational research.
-
Neticonazole Hydrochloride: From Mycosis to Models
2026-08-16
Neticonazole Hydrochloride is an imidazole antifungal with established topical relevance and emerging value in colorectal cancer research. This article focuses on evidence boundaries, assay design, and how targeted oral delivery concepts can inform—not replace—mechanistic studies of exosome inhibition and apoptosis.